Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Swift

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Medicine, Science, and the Law|August 6, 2003
The Shipman inquiry: a progress reportCaroline Swift
JMIR Diabetes|May 20, 2026
Predicting Treatment Failure With Sodium-Glucose Cotransporter-2 Inhibitors in People With Type 2 Diabetes: Novel Artificial Intelligence and Machine Learning ApproachDoyoung Kwak, Xi Tan, Yuanjie Liang, et al.
Clinical Therapeutics|March 31, 2021
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage PopulationJay Visaria, Chioma Uzoigwe, Caroline Swift, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 9, 2026
Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss CategoryAngelo Navas, Joshua Noone, Nathan Laney, et al.
Advances in Therapy|April 30, 2026
Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort StudyXi Tan, Wan-Lun Tsai, Yuanjie Liang, et al.
Current Medical Research and Opinion|October 22, 2025
Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVDXi Tan, Yuanjie Liang, Lin Xie, et al.
Diabetes, Obesity & Metabolism|January 9, 2026
Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United StatesXi Tan, Yuanjie Liang, Lin Xie, et al.
Diabetes Research and Clinical Practice|September 11, 2025
Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVDXi Tan, Joanna Harton, Cynthia Gutierrez, et al.
American Journal of Preventive Cardiology|January 30, 2026
Impact of peripheral artery disease (PAD) on risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetesJames Amamoo, Lin Xie, Andrea Steffens, et al.
Clinical Therapeutics|January 18, 2025
Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for DiabetesCaroline Swift, Monica Frazer, Andrew Sargent, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Medicine, Science, and the Law|August 6, 2003
The Shipman inquiry: a progress reportCaroline Swift
JMIR Diabetes|May 20, 2026
Predicting Treatment Failure With Sodium-Glucose Cotransporter-2 Inhibitors in People With Type 2 Diabetes: Novel Artificial Intelligence and Machine Learning ApproachDoyoung Kwak, Xi Tan, Yuanjie Liang, et al.
Clinical Therapeutics|March 31, 2021
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage PopulationJay Visaria, Chioma Uzoigwe, Caroline Swift, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 9, 2026
Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss CategoryAngelo Navas, Joshua Noone, Nathan Laney, et al.
Advances in Therapy|April 30, 2026
Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort StudyXi Tan, Wan-Lun Tsai, Yuanjie Liang, et al.
Current Medical Research and Opinion|October 22, 2025
Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVDXi Tan, Yuanjie Liang, Lin Xie, et al.
Diabetes, Obesity & Metabolism|January 9, 2026
Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United StatesXi Tan, Yuanjie Liang, Lin Xie, et al.
Diabetes Research and Clinical Practice|September 11, 2025
Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVDXi Tan, Joanna Harton, Cynthia Gutierrez, et al.
American Journal of Preventive Cardiology|January 30, 2026
Impact of peripheral artery disease (PAD) on risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetesJames Amamoo, Lin Xie, Andrea Steffens, et al.
Clinical Therapeutics|January 18, 2025
Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for DiabetesCaroline Swift, Monica Frazer, Andrew Sargent, et al.
Pageof 2